Comparative Pharmacology
Head-to-head clinical analysis: EVEX versus STILPHOSTROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EVEX versus STILPHOSTROL.
EVEX vs STILPHOSTROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Estrogen receptor agonist; binds to and activates nuclear estrogen receptors, leading to gene transcription and cellular effects in target tissues.
Synthetic nonsteroidal estrogen; binds to estrogen receptors, inducing tumor regression in hormone-sensitive cancers.
0.625-1.25 mg orally once daily; or 0.3-0.625 mg vaginally once daily for 21 days with 7 days off.
0.5-1 mg/kg intravenously daily for 5 days, then 0.5 mg/kg intramuscularly weekly.
None Documented
None Documented
Terminal elimination half-life is 12-24 hours, with a mean of approximately 18 hours. Due to significant enterohepatic recirculation, the half-life may be prolonged in patients with hepatic impairment or when administered with drugs that inhibit recirculation.
Terminal elimination half-life: 50-60 hours (range 40-80 hr) due to enterohepatic recirculation; clinical context: steady-state achieved in ~10-14 days
Primarily hepatic metabolism with renal excretion of metabolites; approximately 60% of a dose is excreted in urine as conjugates (glucuronides and sulfates) and 30% in feces via biliary elimination. Less than 5% is excreted unchanged in urine.
Renal (primarily as glucuronide conjugates, 70-80%); fecal (biliary excretion of conjugates, 20-30%); <5% unchanged
Category C
Category C
Estrogen
Estrogen